Etoposide-VP-16-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEEtoposideCat.No.:HY-13629CASNo.:33419-42-0Synonyms:VP-16;VP-16-213分⼦式:C₂₉H₃₂O₁₃分⼦量:588.56作⽤靶点:Topoisomerase;Autophagy;Mitophagy;Bacterial;Apoptosis;Antibiotic作⽤通路:CellCycle/DNADamage;Autophagy;Anti-infection;Apoptosis储存⽅式:4°C,protectfromlight*Insolvent:-80°C,6months;-20°C,1month(protectfrom

light)溶解性数据体外实验DMSO:≥39mg/mL(66.26mM)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制备储备液1mM1.6991mL8.4953mL16.9906mL5mM0.3398mL1.6991mL3.3981mL10mM0.1699mL0.8495mL1.6991mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month(protectfromlight)。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE1.请依序添加每种溶剂：1%DMSO>>99%salineSolubility:≥0.5mg/mL(0.85mM);Clearsolution2.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(4.25mM);Clearsolution3.请依序添加每种溶剂：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(4.25mM);Clearsolution4.请依序添加每种溶剂：5%DMSO>>40%PEG300>>5%Tween-80>>50%salineSolubility:≥2.5mg/mL(4.25mM);Clearsolution5.请依序添加每种溶剂：5%DMSO>>95%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(4.25mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性Etoposide(VP-16;VP-16-213)⼀种常⽤的抗肿瘤化疗剂。Etoposide抑制拓扑异构酶II(topoisomerase-II)，从⽽抑制DNA复制。Etoposide诱导细胞周期停滞，凋亡(apoptosis)和⾃噬(autophagy)。IC50&TargetTopoisomeraseII体外研究Etoposideiscapableofcausingcytotoxicityonpancreaticβ-cellsbyinducingapoptosisthroughtheJNK/ERK-mediatedGSK-3downstream-triggeredmitochondria-dependentsignalingpathwayinRIN-m5Fcells[1].EtoposideandAnti-HumanVEGFsignificantlyabolishP1sphere-formingability,aneffectassociatedwithapoptosisofthissubsetofcells[2].Etoposidephosphate(0-1μM;72hours)inhibitsHCT116FBXW+/+,FBXW-/-andp53-/-asadose-dependentmanner,exhibitsIC50sof0.945μM;0.375μM;and1.437μM,respectively[5].Etoposide(25μM;6hours)delaysp53recoverinFBXW7-deficientcells.Inaddition,FBXW7expressionisdisappearedinFBXW7-/-cells[5].CellViabilityAssay[5]CellLine:HCT116FBXW+/+,FBXW-/-andp53-/-cellsConcentration:0.025μM,0.05μM,0.075μM,0.1μM,0.2μM,0.4μM,0.6μM,0.8μM,1μMIncubationTime:72hoursResult:InhibitsHCT116FBXW+/+p>,FBXW-/-andp53-/-cellgrowthasaconcentrationmanner.WesternBlotAnalysis[5]CellLine:HCT116FBXW7+/+orFBXW7-/-cellsConcentration:25μMIncubationTime:6hoursResult:Exhibitedthattherecoveryofp53levelsafterDNAdamageismediatedbyFBXW7.2/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE体内研究Etoposide(50μM)andAnti-HumanVEGF-treatedhypoxiccellsinjectedintravenouslyintoimmunodeficientmicerevealsareducedcapacitytoinducelungcolonies,whichalsoappearwithalongerlatencyperiod[2].Etoposide(10mg/kg/day,i.v.)withNSC109724andNSC241240,reducesthetumorvolumeinthehepatoblastomacellinjectedNMRInudemice[3].户使⽤本产品发表的科研⽂献•Immunity.2022Aug9;55(8):1370-1385.e8.•AdvSci(Weinh).2020Sep28;7(21):2001364.•JExtracellVesicles.2022Apr;11(4):e12206.•Hepatology.2020May;71(5):1660-1677.•ProteinCell.2022Jan;13(1):47-64.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].LeeKI,etal.Etoposideinducespancreaticβ-cellscytotoxicityviatheJNK/ERK/GSK-3signaling-mediatedmitochondria-dependentapoptosispathway.ToxicolInVitro.2016Jul26.pii:S0887-2333(16)30147-3.[2].CalvaniM,detal.Etoposide-Anti-HumanVEGFanewstrategyagainsthumanmelanomacellsexpressingstem-liketraits.Oncotarget.2016Jun9.doi:10.18632/oncotarget.9939.[3].Fuchs,J.,etal.ComparativeactivityofNSC119875,NSC109724,NSC123127,NSC241240,andetoposideinheterotransplantedhepatoblastoma.Cancer,1998.83(11):p.2400-7.[4].HandeKR,etal.TheImportanceofDrugSchedulinginCancerChemotherapy:EtoposideasanExample.Oncologist.1996;1(4):234-239.[5].CuiD,etal.FBXW7ConfersRadiationSurvivalbyTargetingp53forDegradation.CellRep.2020Jan14;30(2):